AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower level of education (illiterate)
Number of subjects: 382
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower level of education (grade 1-8)
Number of subjects: 382
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of TB using a chest X‐ray
Number of subjects: 382
Study 26805699 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercise
Number of subjects: 105
Study 26805699 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility exercise
Number of subjects: 105
Study 26805699 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 24971565 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis (6 consecutive monthly doses)
Number of subjects: 127
Study 24971565 — intervention group
Group type: COMPARATOR
Intervention: Control group (historic control, no palivizumab prophylaxis)
Number of subjects: 127
Study 22296874 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-At-Every-Size (HAES) intervention
Number of subjects: 0
Study 22296874 — intervention group
Group type: COMPARATOR
Intervention: Social support intervention
Number of subjects: 0
Study 22296874 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19789374 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 6
Study 18724035 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flushing method
Number of subjects: 40
Study 18724035 — intervention group
Group type: COMPARATOR
Intervention: Balloon-occlusion method
Number of subjects: 40
Study 15930349 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI-007 (260 mg/m², 30 minutes; n = 14)
Number of subjects: 27
Study 15930349 — intervention group
Group type: COMPARATOR
Intervention: Taxol (175 mg/m², 3 hours; n = 13)
Number of subjects: 27
Study 14617243 — intervention group
Group type: EXPERIMENTAL
Intervention: Milligan‐Morgan procedure (Group 1, n = 25)
Number of subjects: 50
Study 14617243 — intervention group
Group type: COMPARATOR
Intervention: Stapled haemorrhoidectomy (Group 2, n = 25)
Number of subjects: 50
Study 10795956 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST, n = 61)
Number of subjects: 141
Study 10795956 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling plus Exercise (BEX, n = 39)
Number of subjects: 141
Study 10795956 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling plus Nicotine Gum (BNIC, n = 41)
Number of subjects: 141
Study 8967905 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil 200 mg t.i.d.
Number of subjects: 101
Study 8967905 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg t.i.d.
Number of subjects: 101
Study 8447204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adenosine (30 micrograms.kg‐1.min‐1 for 4 hours)
Number of subjects: 16
Study 8447204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8447204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adenosine
Number of subjects: 16
Study 3082450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive programme by general practitioners (educational consultation and four follow up visits)
Number of subjects: 200
Study 3082450 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational consultation and first follow up visit
Number of subjects: 200
Study 3082450 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of treatment programme and attendance at all follow up visits
Number of subjects: 200
Study 3082450 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 200
Study 29431452 — intervention group
Group type: EXPERIMENTAL
Intervention: Milkshake prime (Prime condition)
Number of subjects: 128
Study 29431452 — intervention group
Group type: COMPARATOR
Intervention: No-Prime (Control condition)
Number of subjects: 128
Study 29431452 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Prime and No-Prime)
Number of subjects: 128
Study 29282948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided injection group
Number of subjects: 120
Study 29282948 — intervention group
Group type: COMPARATOR
Intervention: Palpation guided injection group
Number of subjects: 120
Study 25156227 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 25156227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study 25156227 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person urine testing
Number of subjects: 0
Study 25156227 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0
Study 25156227 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 0
Study 23408223 — intervention group
Group type: EXPERIMENTAL
Intervention: CoughStim™ (ultrasonic cough stimulator) at 0.58 MHz and 9 W unilaterally
Number of subjects: 22
Study 23408223 — intervention group
Group type: EXPERIMENTAL
Intervention: CoughStim™ (ultrasonic cough stimulator) at 0.58 MHz and 6 W bilaterally
Number of subjects: 22
Study 23408223 — intervention group
Group type: EXPERIMENTAL
Intervention: CoughStim™ (ultrasonic cough stimulator) at 0.54 MHz and 6 W bilaterally
Number of subjects: 22
Study 21095483 — intervention group
Group type: EXPERIMENTAL
Intervention: lersivirine 500 mg BID
Number of subjects: 66
Study 21095483 — intervention group
Group type: EXPERIMENTAL
Intervention: lersivirine 750 mg once daily
Number of subjects: 66
Study 21095483 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg once daily
Number of subjects: 66
Study 21095483 — intervention group
Group type: COMPARATOR
Intervention: placebo once daily
Number of subjects: 66
Study 18717168 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 30
Study 18717168 — intervention group
Group type: EXPERIMENTAL
Intervention: SE with Clearfil Flow FX (SE+FX)
Number of subjects: 30
Study 18717168 — intervention group
Group type: COMPARATOR
Intervention: ED Primer II (ED)
Number of subjects: 30
Study 18717168 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F2.0 (PA)
Number of subjects: 30
Study 18717168 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil DC Core Automix (DC)
Number of subjects: 30
Study 16230264 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 446
Study 12854799 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Conventional framework design with parallel fibers (19 restorations)
Number of subjects: 41
Study 12854799 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Modified framework design with parallel and woven fibers (22 restorations)
Number of subjects: 41
Study 12854799 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study 10794048 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptothermal double-check methods
Number of subjects: 1328
Study 10794048 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptothermal single-check methods
Number of subjects: 1328
Study 9101834 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + adjuvant IORT (28 Gy to the celiac axis)
Number of subjects: 115
Study 9101834 — intervention group
Group type: COMPARATOR
Intervention: Surgery (non-IORT)
Number of subjects: 115
Study 1990191 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of acyclovir orally two times per day (suppressive therapy)
Number of subjects: 525
Study 1990191 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of acyclovir five times per day for 5 days (for recurrences)
Number of subjects: 525
Study 1990191 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily acyclovir therapy (suppressive therapy)
Number of subjects: 525
Study 1990191 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute therapy followed by suppressive therapy
Number of subjects: 525
Study 1990191 — intervention group
Group type: COMPARATOR
Intervention: Baseline recurrence rate
Number of subjects: 525
Study 6147703 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 347
Study 6147703 — intervention group
Group type: COMPARATOR
Intervention: CNS prophylaxis
Number of subjects: 347
Study 30471242 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication group
Number of subjects: 1636
Study 30471242 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 1636
Study 30471242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1636
Study 30571697 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Prescriptions (Talking Rx) intervention including Daily Interactive Voice Response (IVR) call services, Daily tailored medication reminders, and Weekly lifestyle modification messages for 3 months.
Number of subjects: 197
Study 30571697 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Prescriptions (Talking Rx) intervention for CVA patients.
Number of subjects: 197
Study 30571697 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control).
Number of subjects: 197
Study 27402605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 35
Study 27402605 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 35
Study 24655537 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen (low‐oxygen group)
Number of subjects: 193
Study 24655537 — intervention group
Group type: COMPARATOR
Intervention: 65% oxygen (high‐oxygen group)
Number of subjects: 193
Study 22490713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban (25 µg/kg bolus followed by 0.15 µg×kg(‐1)×min(‐1) infusion for 36 hours, n = 40)
Number of subjects: 120
Study 22490713 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose tirofiban (10 µg/kg bolus followed by 0.15 µg×kg(‐1)×min(‐1) infusion for 36 hours, n = 40)
Number of subjects: 120
Study 22490713 — intervention group
Group type: COMPARATOR
Intervention: No tirofiban (n = 40)
Number of subjects: 120
Study 22490713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban
Number of subjects: 120
Study 22490713 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose tirofiban
Number of subjects: 120
Study 20169258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular administration of 10 mg of morphine
Number of subjects: 50
Study 20169258 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular administration of 20 mL of NS
Number of subjects: 50
Study 17389291 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based GIOP intervention
Number of subjects: 949
Study 17389291 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based GIOP intervention (among 45 physicians completing all modules)
Number of subjects: 949
Study 16093416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive broad‐based home exercise program targeting flexibility, strength, balance, and endurance (30 half‐hour sessions)
Number of subjects: 20
Study 16093416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 11984100 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐SELF Pain Control Program
Number of subjects: 11
Study 11984100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management autobiographies (qualitative analysis)
Number of subjects: 11
Study 11984100 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual or family counseling or alternative pain management strategies
Number of subjects: 11
Study 10460042 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone transscrotal patch (6 mg/day)
Number of subjects: 133
Study 10460042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 8546997 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly MPD-PUVA
Number of subjects: 83
Study 8546997 — intervention group
Group type: COMPARATOR
Intervention: Three times-weekly skin typing-PUVA
Number of subjects: 83
Study 2241822 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (first test while having pain)
Number of subjects: 30
Study 2241822 — intervention group
Group type: COMPARATOR
Intervention: Group B (first test without pain)
Number of subjects: 30
Study 318984 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg LOX
Number of subjects: 0
Study 318984 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg LOX
Number of subjects: 0
Study 318984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31524140 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-specific training (COR)
Number of subjects: 20
Study 31524140 — intervention group
Group type: COMPARATOR
Intervention: Typical training (CON)
Number of subjects: 20
Study 31339826 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (375 mg/m2, once every 8 weeks for 2 years)
Number of subjects: 1018
Study 31339826 — intervention group
Group type: COMPARATOR
Intervention: Observation (no additional treatment)
Number of subjects: 1018
Study 31339826 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 1018
Study 31339826 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1018
Study 28427883 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright bag-mask
Number of subjects: 328
Study 28427883 — intervention group
Group type: COMPARATOR
Intervention: Standard bag-mask
Number of subjects: 328
Study 26521572 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-point needle-retaining therapy + training (group A)
Number of subjects: 66
Study 26521572 — intervention group
Group type: COMPARATOR
Intervention: Training after acupuncture (group B)
Number of subjects: 66
Study 23140517 — intervention group
Group type: EXPERIMENTAL
Intervention: Test paste containing 8% arginine and calcium carbonate (elmex sensitive professional desensitizing paste)
Number of subjects: 30
Study 23140517 — intervention group
Group type: COMPARATOR
Intervention: Control paste: paris white (calcium carbonate)
Number of subjects: 30
Study 22000343 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (study group) with vaginal introital defects
Number of subjects: 128
Study 22000343 — intervention group
Group type: COMPARATOR
Intervention: Group II (control) without vaginal introital defects
Number of subjects: 128
Study 22000343 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group I and Group II
Number of subjects: 128
Study 19220493 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 433
Study 19220493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents
Number of subjects: 433
Study 19220493 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitors
Number of subjects: 433
Study 19220493 — intervention group
Group type: COMPARATOR
Intervention: Nonnucleoside reverse transcriptase inhibitors (NNRTIs), particularly efavirenz
Number of subjects: 433
Study 17967650 — intervention group
Group type: EXPERIMENTAL
Intervention: Open food challenge (OFC)
Number of subjects: 20
Study 17967650 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge (DBPCFC)
Number of subjects: 20
Study 17967650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15005866 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial memory task
Number of subjects: 0
Study 15005866 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-spatial memory task
Number of subjects: 0
Study 15005866 — intervention group
Group type: COMPARATOR
Intervention: Control (no cognitive task)
Number of subjects: 0
Study 11338761 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel/mild soap
Number of subjects: 0
Study 11338761 — intervention group
Group type: COMPARATOR
Intervention: Mild soap alone
Number of subjects: 0
Study 10210991 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment in prepubertal children
Number of subjects: 22
Study 10210991 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhGH) in prepubertal children
Number of subjects: 22
Study 10210991 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment in pubertal children
Number of subjects: 22
Study 10210991 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhGH) in pubertal children
Number of subjects: 22
Study 10210991 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment
Number of subjects: 22
Study 10210991 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhGH)
Number of subjects: 22
Study 8180766 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 39
Study 8180766 — intervention group
Group type: COMPARATOR
Intervention: Conventional cholecystectomy
Number of subjects: 39
Study 3356152 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drug study with centralized case validation system
Number of subjects: 622
Study 3356152 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted extra support for patients with known problems at entry
Number of subjects: 622
Study 3356152 — intervention group
Group type: EXPERIMENTAL
Intervention: Case categorization at entry
Number of subjects: 622
Study 30045822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 860
Study 28131794 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib
Number of subjects: 334
Study 28131794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 26201709 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 1059
Study 26201709 — intervention group
Group type: COMPARATOR
Intervention: Placebo/SOC
Number of subjects: 1059
Study 23877864 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 4 µg/kg intravenously
Number of subjects: 80
Study 23877864 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1 mg/kg
Number of subjects: 80
Study 20375299 — intervention group
Group type: EXPERIMENTAL
Intervention: GIN therapy (insulin at 2 mU . kg(‐1) . min(‐1) during surgery, decreased to 1 mU . kg(‐1) . min(‐1) for 24 hours, dextrose 20% infusion)
Number of subjects: 52
Study 20375299 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (conventional insulin sliding scale)
Number of subjects: 52
Study 20375299 — intervention group
Group type: EXPERIMENTAL
Intervention: GIN therapy
Number of subjects: 52
Study 18708248 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved oxygen system (oxygen concentrators and pulse oximeters) introduced in five hospitals.
Number of subjects: 11000
Study 16773643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-force eccentric resistance training (3 days a week for 12 weeks)
Number of subjects: 19
Study 16773643 — intervention group
Group type: COMPARATOR
Intervention: Standard-care control
Number of subjects: 19
Study 14668667 — intervention group
Group type: EXPERIMENTAL
Intervention: Picker questionnaire
Number of subjects: 2850
Study 14668667 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Judgment System (PJS)
Number of subjects: 2850
Study 14668667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequs
Number of subjects: 2850
Study 14668667 — intervention group
Group type: EXPERIMENTAL
Intervention: Lausanne questionnaire
Number of subjects: 2850
Study 11198135 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 9
Study 11198135 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 9
Study 11198135 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 9
Study 8826226 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 0
Study 8826226 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate
Number of subjects: 0
Study 8826226 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 0
Study 1591737 — intervention group
Group type: EXPERIMENTAL
Intervention: Milacemide
Number of subjects: 0
Study 4000324 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide meal
Number of subjects: 24
Study 4000324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono- and disaccharide meal
Number of subjects: 24
Study 4000324 — intervention group
Group type: EXPERIMENTAL
Intervention: All meals (including polysaccharide, mono- and disaccharide)
Number of subjects: 24
Study 31786872 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with interval cytoreductive surgery
Number of subjects: 178
Study 31786872 — intervention group
Group type: COMPARATOR
Intervention: Primary cytoreductive surgery alone
Number of subjects: 178
Study 29188298 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus RT (2 cycles of gemcitabine 1000 mg/m2 on days 1, 8, and 15, and cisplatin 70 mg/m2 on day 2, followed by RT to 4500 cGy in 150 cGy twice-daily fractions over 3 weeks)
Number of subjects: 120
Study 29188298 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (4 cycles of gemcitabine and cisplatin)
Number of subjects: 120
Study 29188298 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus RT
Number of subjects: 120
Study 29188298 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 120
Study 27075990 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) consisting of three 5-minute cycles of upper limb cuff occlusion with 5-minutes of reperfusion, both 24 hours and immediately before surgery.
Number of subjects: 85
Study 27075990 — intervention group
Group type: COMPARATOR
Intervention: Control group received a similarly timed sham treatment.
Number of subjects: 85
Study 27075990 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC
Number of subjects: 85
Study 27075990 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 85
Study 24913220 — intervention group
Group type: EXPERIMENTAL
Intervention: Text2Quit
Number of subjects: 503
Study 24913220 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported smoking cessation
Number of subjects: 503
Study 24913220 — intervention group
Group type: COMPARATOR
Intervention: Self-help material
Number of subjects: 503
Study 22093057 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 1000 mg
Number of subjects: 120